OXIDATIVE STRESS IN PATHOGENESIS OF DIABETIC MICRO- AND MACROANGIOPATHY AS A TARGET FOR THERAPEUTIC IMPACT

Authors

DOI:

https://doi.org/10.21856/j-PEP.2012.3.14

Keywords:

diabetes mellitus, diabetic complications, free radicals, stress-activated signaling pathways, α-lipoic acid

Abstract

The review is devoted to the pathogenic role of oxidative stress in specific and nonspecific diabetic
vascular complications development. Perspectives of antioxidant therapy, in particular, α-lipoic acid,
in order to restore redox homeostasis and eliminate the negative consequences of its imbalance are
grounded.

References

Giacco, F. Oxidative stress and diabetic complications [Text] / F. Giacco, M. Brownlee // Cir. Res. — 2010. — Vol. 107. — P. 1058–1070.

Aronson, D. How hyperglycemia promotes atherosclerosis: molecular mechanisms [Text] / D. Aronson, E. J. Rayfield // Cardiovasc. Dia-

betol. — 2002. — Vol. 1. — P. 1–10.

Effect of a multifactorial intervention on mortality in type 2 diabetes [Text] / P. Gaede, H. Lund-Andersen, H. H. Parving [et al.] // N. Eng. J. Med. — 2008. — Vol. 358. — P. 580–591.

Förstermann, U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies [Text] / U. Förstermann // Nat. Clin. Pract. Cardiovasc. Med. — 2008. — Vol. 5, № 6. — P. 338–349.

Brownlee, M. Biochemistry and molecular cell biology of diabetic complications [Text] / M. Brownlee // Nature. — 2001. — Vol. 414. — P. 813–820.

Maillard reaction, mitochondria and oxidative stress: potential role of antioxidants [Text] / M. Edeas, D. Attaf, A. S. Mailfert [et al.] // Pathol. Biol. (Paris). — 2010. — Vol. 58, № 3. — P. 220–225.

Brownlee, M. Negative consequences of glycation [Text] / M. Brownlee // Metabolism. — 2000. — Vol. 49. — P. 9–13.

Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism [Text] / M. Brownlee // Diabetes. — 2005. — Vol. 54. — P. 1615–1625.

Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes [Text] / J. L. Evans, I. D. Goldfine, B. A. Maddux, G. M. Grodsky // Endocrine Rev. — 2002. — Vol. 23, № 5. — P. 599–622.

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes [Text] / I. M. Wentholt, W. Kulik, R. P. Michels

[et al.] // Diabetologia. — 2008. — Vol. 51, № 1. — P. 183–190.

Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation[Text] / F. Zheng, W. Lu, C. Jia [et al.] // Endocrine. — 2010. — Vol. 37, № 1. — P. 201–208.

Sivitz W. I. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities [Text] / W. I. Sivitz, M. A. Yorek // Antioxid. Red. Signal. — 2010. — Vol. 12, № 4. — P. 537–577.

No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients [Text] / S. E. Siegelaar, T. Barwari, W. Kulik [et al.] // J. Diabet. Sci. Technol. — 2011. — Vol. 5, № 1. — P. 86–92.

Wajchenberg, B. L. Postprandial glycemia and cardiovascular disease in diabetes mellitus [Text] / B. L. Wajchenberg // Arq. Bras. Endocrinol. Metabol. — 2007. — Vol. 51, № 2. — P. 212–221.

Dröge W. Free radicals in the physiological control of cell function [Text] / W. Dröge // Physiol. Rev. — 2002. — Vol. 82. — P. 47–95.

Oxidative stress in the pathogenesis of diabetic neuropathy [Text] / A. M. Vincent, J. W. Russel, P. Low, E. L. Feldman // Endocrinol. Rev. — 2004. — Vol. 25, № 4. — P. 612–628. (17)

Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE [Text] / M. P. Wautier, O. Chappey, S. Corda [et al.] // Am. J. Physiol. — 2001. — Vol. 280. — P. E685–694. (27)

Forbes, J. M. Oxidative stress as a major culprit in kidney disease in diabetes [Text] / J. M. Forbes, M. T. Coughlan, M. E. Cooper // Diabetes — 2008. — Vol. 57. — P. 1446–1454. (28)

Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism [Text] / W. Deuter-Conrad, C. Loske, R. Schinzel [et al.] // Neurosci. Lett. — 2001. — Vol. 312. — P. 29–32. (29)

Roles of the AGE–RAGE system in vascular injury in diabetes [Text] / Y. Yamamoto, S. Yamagishi, H. Yonekura [et al.] // Ann. N. Y. Acad. Sci. — 2000. — Vol. 902. — P. 163–170. (30)

Das Evcimen, N. The role of protein kinase C activation and the vascular complications of diabetes [Text] / N. Das Evcimen, G. L. King // Pharmacol. Res. — 2007. –Vol. 55, № 6. — P. 498–510. (35)

Turrens, J. F. Mitochondrial formation of reactive oxygen species [Text] / J. F. Turrens // J. Physiol. — 2003. — Vol. 552, Pt. 2. — P. 335–344. (36)

Patel, S. Role of NF- κ B in the pathogenesis of diabetes and its associated complications [Text] / S. Patel, D. Santani // Pharmacol. Rep. — 2009. — Vol. 61, № 4. — P. 595–603.

Valen, G. Nuclear factor kappa-B and the heart [Text] / G. Valen, Z. Q. Yan, G. K. Hansson // J. Am. Coll. Cardiol. — 2001. — Vol. 38, № 2. — P. 307–314.

Fang, Z. Y. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications [Text] / Z. Y. Fang, J. B. Prins, T. H. Marwick // Endocrinol. Rev. — 2004. — Vol. 25, № 4. — P. 543–567.

Baker, R. G. NF- κ B, inflammation and metabolic disease [Text] / R. G. Baker, M. S. Hayden, S. Ghosh // Cell. Metabol. — 2011. — Vol. 13, № 1. — P. 11–22.

The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy [Text] / F. B. Valiatti, D. Crispim, C. Benfica [et al.] // Arq. Bras. Endocrinol. Metabol. — 2011. — Vol. 55, № 2. — P. 106–113.

Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications [Text] / F. Chiarelli, A. Spagnoli, F. Basciani [et al.] // Diabet. Med. — 2000. — Vol. 17. — P. 650–656.

Mironidou-Tzouveleki, M. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus [Text] / M. Mironidou-Tzouveleki, S. Tsartsalis, C. Tomos // Curr. Drug. Targets. — 2011. — Vol. 12, No 1. — P. 107-114.

Vascular endothelial growth factor in diabetic nephropathy [Text] / T. Lenz, T. Haak, J. Malek [et al.] // Kidney Blood Press. Res. — 2003. — Vol. 26, № 5–6. — P. 338–343.

Wirostko, B. Vascular endothelial growth factor and diabetic complications [Text] / B. Wirostko, T. Y. Wong, R. Simó // Prog. Retin. Eye Res. — 2008. — Vol. 27, № 6. — P. 608–621.

Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage [Text] / T. Deguchi, T. Hashiguchi, S. Horinouchi [et al.] // Diabet. Med. — 2009. — Vol. 26, № 3. — P. 247–252.

Stocker, R. Jr. Role of oxidative modifications in atherosclerosis [Text] / R. Stocker, J. F. Keaney // Physiol. Rev. — 2004. — Vol. 84. — P. 1381–1478.

Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NF κ B: implications for tolerance induction [Text] / S. T. Smiley, V. Csizmadia, W. Gao [et al.] // Transplantation. — 2000. — Vol. 70, № 3. — P. 415–419.

Yin, M. J. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I κ B kinase [Text] / M. J. Yin, Y. Yamamoto, R. B. Gaynor // Nature. — 1998. — Vol. 396. — P. 77–80.

Barnes, P. J. Glucocorticoid resistance in inflammatory diseases [Text] P. J. Barnes, I. M. Adcock // Lancet. — 2009. — Vol. 373, № 9678. — P. 1905–1917.

Hall, G. Regulating the regulator: NF- κ B signaling in heart [Text] / G. Hall, J. D. Hasday, T. B. Rogers // J. Mol. Cell. Cardiol. — 2006. — Vol. 41, № 4. — P. 580–591.

Inhibition of nuclear factor κ B by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression [Text] / Q. Ma, K. Kinneer, J. Ye, B. J. Chen // Mol. Pharm. — 2003. — Vol. 64, № 2. — P. 211–219.

Zhang, W. J. α -Lipoic acid inhibits TNF- α -induced NF- κ B activation and adhesion molecule expression in human aortic endothelial cells [Text] / W. J. Zhang, B. Frei // FASEB. — 2001. — Vol. 15. — P. 2423–2432.

Houston, M. C. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease [Text] / M. C. Houston // Ther. Adv. Cardiovasc. Dis. — 2010. — Vol. 4, № 3. — P. 165–183.

Golbidi, S. Antioxidant therapy in human endocrine disorders [Text] / S. Golbidi, I. Laher // Med. Sci. Monit. — 2010. — Vol. 16, № 1. — P. RA9–24.

Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [Text] / S. Yusuf, G. Dagenais, J. Pogue [et al.] // N. Engl. J. Med. — 2000. — Vol. 342, № 3. — P. 154–160.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial [Text] / M. Sacco, F. Pellegrini, M. C. Roncaglioni [et al.] // Diabetes Care. — 2003. — Vol. 26, № 12. — P. 3264–3272.

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [Text] / M. Boaz, S. Smetana, T. Weinstein [et al.] // Lancet. — 2000. — Vol. 356, № 9237. — P. 1213–1218.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [Text] / P. Gaede, P. Vedel, N. Larsen [et al.] // N. Engl. J. Med. — 2003. — Vol. 348, № 5. — P. 383–393.

Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice [Text] / J. Schultz Johansen, A. K. Harris, D. J. Rychly, A. Ergul // Cardiovasc. Diabetol. — 2005. — Vol. 4, № 5. — P. 1–11.

Antioxidant therapy: current status and future prospects [Text] / O. Firuzi, R. Miri, M. Tavakkoli, L. Saso // Curr. Med. Chem. — 2011. — Vol. 18. — P. 3871–3888.

Golbidi, S. Antioxidants in the treatment of diabetes [Text] / S. Golbidi, S. A. Ebadi, I. Laher // Curr. Diabetes Rev. — 2011. — Vol. 7, № 2. — P. 106–125.

α -Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials [Text] / D. Ziegler, M. Reljanovic, H. Mehnert, F. A. Gries // Exp. Clin. Endocrinol. Diabetes. — 1999. — Vol. 107, № 7. — P. 421–430.

Singh, U. Alpha-lipoic acid supplementation and diabetes [Text] / U. Singh, I. Jialal // Nutr. Rev. — 2008. — Vol. 66, № 11. — P. 646–657.

Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (AL-ADIN Study) [Text] / D. Ziegler, M. Hanefeld, K. J. Ruhnau [et al.] // Diabetologia. — 1995. — Vol. 38, № 12. — P. 1425–1433.

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebocontrolled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy [Text] / M. Reljanovic, G. Reichel, K. Rett [et al.] // Free Radic. Res. — 1999. — Vol. 31, № 3. — P. 171–179.

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy [Text] / D. Ziegler, M. Hanefeld, K. J. Ruhnau [et al.] // Diabetes Care. — 1999. — Vol. 22, № 8. — P. 1296–1301.

Effects of treatment with the antioxidant alphalipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie [Text] / D. Ziegler, H. Schatz, F. Conrad [et al.] // Diabetes Care. — 1997. — Vol. 20, № 3. — P. 369–373.

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [Text] / A. S. Ametov, A. Barinov, P. J. Dyck [et al.] // Diabetes Care. — 2003. — Vol. 26, № 3. — P. 770–776.

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a metaanalysis[Text] / D. Ziegler, H. Nowak, P. Kempler [et al.] // Diabet Med. — 2004. — Vol. 21, № 2. — P. 114–121.

Foster, T. S. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy [Text] / T. S. Foster // Diabetes Educ. –2007. — Vol. 33. — P. 111–117.

Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study [Text] / M. Morcos, V. Borcea, B. Isermann [et al.] // Diabetes Res. Clin. Pract. –2001. — Vol. 52. — P. 175–183.

Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress [Text] / T. Heitzer, B. Finckh, S. Albers [et al.] // Free Radic. Biol. Med. — 2001. — Vol. 31. — P. 53–61.

Kamenova, P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid [Text] / P. Kamenova // Hormones (Athens). — 2006. — Vol. 5. — P. 251–258.

Maritim, A. C. Effects of α -lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats [Text] / A. C. Maritim, R. A. Sanders, J. B. Watkins III // J. Nutr. Biochem. — 2003. — Vol. 14. — P. 288–294.

Obrosova I. G. Early changes in lipid preoxidation and antioxidative defense in diabetic rat retina: effect of DL α -lipoic acid [Text] / I. G. Obrosova, L. Fathallah, D. A. Greene // Europ. J. Pharmacol. — 2000. — Vol. 398. — P. 139–146.

Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL α -lipoic acid [Text] / I. G. Obrosova, X. Cao, D. A. Greene, M. J. Stevens // Diabetologia. — 1998. — Vol. 41. — P. 1442–1450.

Effecy of antioxidant treatment of streptozotocininduced diabetic rats on endoneural blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of sciatric nerve[Text] / L. J. Coppey, J. S. Gellett, E. P. Davidson [et al.] // Diabetes. — 2001. — Vol. 50. — P. 1927–1937.

The effects of treatment with α -lipoic acid or evening primrose oil on vascular haemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat[Text] / I. Ford, M. A. Cotter, N. E. Cameron, M. Greaves // Metabolism. — 2001. — Vol. 50. — P. 868–875.

Piotrowski, P. Neuronal death in the rat hippocam pus in experimental diabetes and cerebral ischemia treated with antioxidants [Text] / P. Piotrowski, K. Wierzbicka, M. Smialek // Folia Neuropathol. — 2001. — Vol. 39. — P. 147–154.

α -Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy [Text] / X. Yi, V. Nickeleit, L. R. James, N. Maeda // J. Diabet. Complications. — 2011. — Vol. 25, 3. — P. 193–201.

Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production [Text] / A. E. Midaoui, A. Elimadi, L. Wu [et al.] // Am. J. Hypertens. — 2003. — Vol. 16. — P. 173–179.

Additional Files

Published

2012-10-10

How to Cite

Poltorak, V., Krasova, N., & Gorshunska, M. (2012). OXIDATIVE STRESS IN PATHOGENESIS OF DIABETIC MICRO- AND MACROANGIOPATHY AS A TARGET FOR THERAPEUTIC IMPACT. Problems of Endocrine Pathology, 41(3), 91-103. https://doi.org/10.21856/j-PEP.2012.3.14

Most read articles by the same author(s)

1 2 > >>